Joel Kruger suggests this interesting Equities in his section Equities of interest :
Celldex Therapeutics, Inc. (NASD: CLDX)
A nice little run for this one of late and while medium and longer-term technical studies are looking constructive, the short-term horizon is less encouraging. Daily technical studies are well overbought and from here, the risks are tilted to the downside, with the market poised for a healthy corrective pullback towards the $7.50-8.00 area. The market should have a hard time trying to establish any meaningful gains above $9.00.